This study examined the case of 27-year-old female who underwent orthognathic surgery to correct class 3 malocclusion, resulting in an unnatural smile. The research aimed to assess the efficacy of non-invasive treatment in enhancing facial muscle movement during smiling to achieve a natural smile. The patient received eight sessions of treatment using non-invasive devices, and facial assessment were conducted using three-dimensional scanner (Morpheus 3D Scanner) to evaluate facial features in both relaxed and maximum smile states pre- and post-treatment. The results demonstrated improvements in the symmetry of the lower lip height during smiling, along with increases in mouth width and volume in the upper central area. Subjectively, the patient also reported enhanced comfort while smiling. These findings suggest that non-invasive procedures can effectively improve unnatural smiles following orthognathic surgery, contributing to a more aesthetically pleasing smile presentation.

This study examined the case of 27-year-old female who underwent orthognathic surgery to correct class 3 malocclusion, resulting in an unnatural smile. The research aimed to assess the efficacy of non-invasive treatment in enhancing facial muscle movement during smiling to achieve a natural smile. The patient received eight sessions of treatment using non-invasive devices, and facial assessment were conducted using three-dimensional scanner (Morpheus 3D Scanner) to evaluate facial features in both relaxed and maximum smile states pre- and post-treatment. The results demonstrated improvements in the symmetry of the lower lip height during smiling, along with increases in mouth width and volume in the upper central area. Subjectively, the patient also reported enhanced comfort while smiling. These findings suggest that non-invasive procedures can effectively improve unnatural smiles following orthognathic surgery, contributing to a more aesthetically pleasing smile presentation.

This study examined the case of 27-year-old female who underwent orthognathic surgery to correct class 3 malocclusion, resulting in an unnatural smile. The research aimed to assess the efficacy of non-invasive treatment in enhancing facial muscle movement during smiling to achieve a natural smile. The patient received eight sessions of treatment using non-invasive devices, and facial assessment were conducted using three-dimensional scanner (Morpheus 3D Scanner) to evaluate facial features in both relaxed and maximum smile states pre- and post-treatment. The results demonstrated improvements in the symmetry of the lower lip height during smiling, along with increases in mouth width and volume in the upper central area. Subjectively, the patient also reported enhanced comfort while smiling. These findings suggest that non-invasive procedures can effectively improve unnatural smiles following orthognathic surgery, contributing to a more aesthetically pleasing smile presentation.

This study examined the case of 27-year-old female who underwent orthognathic surgery to correct class 3 malocclusion, resulting in an unnatural smile. The research aimed to assess the efficacy of non-invasive treatment in enhancing facial muscle movement during smiling to achieve a natural smile. The patient received eight sessions of treatment using non-invasive devices, and facial assessment were conducted using three-dimensional scanner (Morpheus 3D Scanner) to evaluate facial features in both relaxed and maximum smile states pre- and post-treatment. The results demonstrated improvements in the symmetry of the lower lip height during smiling, along with increases in mouth width and volume in the upper central area. Subjectively, the patient also reported enhanced comfort while smiling. These findings suggest that non-invasive procedures can effectively improve unnatural smiles following orthognathic surgery, contributing to a more aesthetically pleasing smile presentation.

This study examined the case of 27-year-old female who underwent orthognathic surgery to correct class 3 malocclusion, resulting in an unnatural smile. The research aimed to assess the efficacy of non-invasive treatment in enhancing facial muscle movement during smiling to achieve a natural smile. The patient received eight sessions of treatment using non-invasive devices, and facial assessment were conducted using three-dimensional scanner (Morpheus 3D Scanner) to evaluate facial features in both relaxed and maximum smile states pre- and post-treatment. The results demonstrated improvements in the symmetry of the lower lip height during smiling, along with increases in mouth width and volume in the upper central area. Subjectively, the patient also reported enhanced comfort while smiling. These findings suggest that non-invasive procedures can effectively improve unnatural smiles following orthognathic surgery, contributing to a more aesthetically pleasing smile presentation.

Background: To evaluate the degree of deformation in patients with ankle osteoarthritis (OA), it is essential to measure the threedimensional (3D), in other words, stereoscopic alignment of the ankle, subtalar, and foot arches. Generally, measurement of radiological parameters use two-dimensional (2D) anteroposterior and lateral radiographs in a weight-bearing state; however, computeraided 3D analysis (Disior) using weight-bearing cone-beam computed tomography (CBCT) has recently been introduced. Methods: In this study, we compared the 2D human radiographic method with a stereoscopic image in patients with ankle arthritis. We enrolled 57 patients diagnosed with OA (28 left and 29 right) and obtained both standing radiographs and weight-bearing CBCT. Patients were divided by the Takakura stage. The interclass correlation coefficient (ICC) for each result was confirmed. Results: On the ICC between 2D radiographs and 3D analysis, the tibiotalar surface angle and lateral talo-1st metatarsal angle showed a good ICC grade (> 0.6), while other parameters did not have significant ICC results. Three-dimension was superior to radiographs in terms of statistical significance. Conclusions We demonstrated that 2D and stereoscopic images are useful for the diagnosis of OA. Our study also confirmed that the radiographic features affected by ankle OA varied. However, according to the results, the typical radiography is not sufficient to diagnose and determine a treatment plan for ankle OA. Therefore, the method of using 3D images should be considered.

Human Q fever, a zoonosis caused by Coxiella burnetii, presents with diverse clinical manifestations ranging from mild self-limited febrile illnesses to life-threatening complications such as endocarditis or vascular infection. Although acute Q fever is a benign illness with a low mortality rate, a large-scale outbreak of Q fever in the Netherlands led to concerns about the possibility of blood transfusion-related transmission or obstetric complications in pregnant women. Furthermore, a small minority (< 5%) of patients with asymptomatic or symptomatic infection progress to chronic Q fever. Chronic Q fever is fatal in 5–50% of patients if left untreated. In South Korea, Q fever in humans was designated as a notifiable infectious disease in 2006, and the number of Q fever cases has increased sharply since 2015. Nonetheless, it is still considered a neglected and under-recognized infectious disease. In this review, recent trends of human and animal Q fever in South Korea, and public health concerns regarding Q fever outbreaks are reviewed, and we consider how a One Health approach could be applied as a preventive measure to prepare for zoonotic Q fever outbreaks.

Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.

Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.

Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.